The invention provides a medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The invention also provides a method of treating a narrowing in a body passageway comprising placing an implantable medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The medicaments can be incorporated within or coated on the device. The invention further provides hydrophobic analogs of medicaments known to inhibit cell proliferation and migration.

Disclosed herein is a novel hemostatic patch that may be used to control and/or arrest bleeding in patients. The patch offers an effective but also minimally invasive way to control and/or arrest bleeding in a patient. The patch comprises a mucoadhesive and a compound that causes vasoconstriction. In a preferred aspect, the patch comprises chitosan and Neuropeptide Y. Also disclosed are methods of using the novel hemostatic patch.

Disclosed are adjustable accommodating intraocular lenses and methods of adjusting accommodating intraocular lenses post-operatively. In one embodiment, an adjustable accommodating intraocular lens comprises an optic portion and a peripheral portion. At least one of the optic portion and the peripheral portion can be made in part of a composite material comprising an energy absorbing constituent and a plurality of expandable components. At least one of a base power and a cylindricity of the optic portion can be configured to change in response to an external energy directed at the composite material.

Embodiments herein relate to active agent depots formed in situ and related methods. In various embodiments, a method of forming an active agent depot in situ is included. The method can include contacting a composition with a vessel wall, wherein the composition includes an active agent and a fibrin promoting vessel wall transfer agent wherein the ratio of active agent to fibrin promoting vessel wall transfer agent (wt./wt.) is at least 5:1. The method also includes transferring the composition from a device surface to the vessel wall surface. The method also includes forming a fibrin matrix around the composition. Other embodiments are also included herein.

In one aspect, the present disclosure pertains to elutable coating compositions that comprise an excipient comprising a bio-degradable or bio-stable polymer selected from a poly(lactic-co-glycolic acid) (PLGA) or methyl cellulose (MCC), a binding agent; a therapeutic agent. In some embodiments, the elutable coating compositions further comprise a solvent, in which case such compositions may be, for example, applied to a substrate in the form of a layer and subsequently dried, thereby forming an elutable coating on the substrate.

The present invention provides a system comprising: (i) a layer containing a nitrite; and (ii) a hydrogel that contains hydrogen ions. The invention also provides the use of a system of the invention for the treatment of a condition associated with tissue ischaemia or a wound and the use of a system of the invention in combination with an anaesthetic for the treatment or prevention of pain.

Dermal filler hydrogel compositions, methods of making them, and methods of using them to treat soft tissue conditions, such as wrinkles, are provided. The compositions contain a crosslinked hyaluronic acid-based polymer and one or more additional ingredients, and are stable to sterilization by heat and/or pressure treatment. The additional ingredients include vasoconstrictive agents, antioxidant agents, such as a ascorbic acid agents, and/or anesthetic agents.

Provided are injectable, hyaluronic acid-based hydrogel compositions including conjugated vitamins.

The present disclosure relates ionic liquids which are used as lubricants for medical devices. In some aspects, the ionic liquids of the present disclosure can exhibit antimicrobial or host cell integrative activity or a combination of functionalities. In some aspects, the present disclosure also provides devices coated with the ionic liquid.

The present invention relates to inhibiting or preventing infection and protecting against patency complications after a blood catheter has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising: (A) at least one taurinamide derivative, (B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof; and (C) heparin at a low concentration.